Universidad Peruana Cayetano Heredia

Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID)

Mostrar el registro sencillo del ítem

dc.contributor.author Navarro Hoyos, Rafaella Alexandra
dc.contributor.author Paredes, Jose Luis
dc.contributor.author Tucto, Lourdes
dc.contributor.author Medina, Carlos
dc.contributor.author Angles-Yanqui, Eddie
dc.contributor.author Nario, Juan Carlos
dc.contributor.author Ruiz Cabrejos, Jorge
dc.contributor.author Quintana, Juan Luis
dc.contributor.author Turpo-Espinoza, Kevin
dc.contributor.author Mejia-Cordero, Fernando
dc.contributor.author Aphang-Lam, Meylin
dc.contributor.author Florez, Jorge
dc.contributor.author Carrasco Escobar, Gabriel
dc.contributor.author Ochoa Woodell, Theresa Jean
dc.date.accessioned 2023-01-06T13:40:12Z
dc.date.available 2023-01-06T13:40:12Z
dc.date.issued 2022
dc.identifier.uri https://hdl.handle.net/20.500.12866/12999
dc.description.abstract Lactoferrin (LF) has in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This study aimed to determine the effect of bovine lactoferrin (bLF) in the prevention of SARS-CoV-2 infection in health care personnel. A randomized, double-blinded, placebo-controlled clinical trial was conducted in two tertiary hospitals that provide care to patients with SARS-CoV-2 infection in Lima, Peru. Daily supplementation with 600 mg of enteral bLF versus placebo for 90 days was compared. Participants were weekly screened for symptoms suggestive of SARS-CoV-2 infection and molecular testing was performed on suspected episodes. A serological test was obtained from all participants at the end of the intervention. The main outcome included symptomatic and asymptomatic cases. A sub-analysis explored the time to symptomatic infection. Secondary outcomes were the severity, frequency, and duration of symptomatic infection. The study was prematurely cancelled due to the availability of vaccines against SARS-CoV-2 in Peru. 209 participants were enrolled and randomized, 104 received bLF and 105 placebo. SARS-CoV-2 infection occurred in 11 (10.6%) participants assigned to bLF and in 9 (8.6%) participants assigned to placebo without significant differences (Incidence Rate Ratio = 1.23, 95%CI 0.51–3.06, p-value = 0.64). There was no significant effect of bLF on time to symptomatic infection (Hazard Ratio = 1.61, 95%CI 0.62–4.19, p-value = 0.3). There were no significant differences in secondary outcomes. A significant effect of bLF in preventing SARS-CoV-2 infection was not proven. Further studies are needed to assess the effect of bLF supplementation on SARS-CoV-2 infection. en_US
dc.language.iso eng
dc.publisher Springer
dc.relation.ispartofseries BioMetals
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Lactoferrin en_US
dc.subject SARS-CoV-2 en_US
dc.subject Health care personnel en_US
dc.subject Prevention en_US
dc.subject Clinical trial en_US
dc.title Bovine lactoferrin for the prevention of COVID-19 infection in health care personnel: a double-blinded randomized clinical trial (LF-COVID) en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1007/s10534-022-00477-3
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.04.04
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.03
dc.relation.issn 1572-8773


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas